Loading...
•
Sep 30, 2022
Puma Biotechnology Q3 2022 Earnings Report
Reported financial results for the third quarter ended September 30, 2022 and raised FY 2022 NERLYNX net product revenue guidance.
Key Takeaways
Puma Biotechnology reported a net loss of $0.4 million, or $0.01 per share, for the third quarter of 2022. Total revenue for the third quarter of 2022 was $57.1 million, which includes $54.3 million from NERLYNX net product revenue.
Product revenue, net in the third quarter of 2022 was $54.3 million, compared to $43.4 million in the third quarter of 2021.
Puma reported a net loss of $0.4 million, or $0.01 per share, for the third quarter of 2022, compared to a net loss of $44.7 million, or $1.09 per share, for the third quarter of 2021.
Non-GAAP adjusted net income was $2.5 million, or $0.05 per basic and diluted share, for the third quarter of 2022, compared to non-GAAP adjusted net loss of $40.4 million, or $0.99 per share, for the third quarter of 2021.
Net cash provided by operating activities for the third quarter of 2022 was $17.3 million, compared to net cash provided by operating activities of $10.5 million in the third quarter of 2021.
Revenue by Segment
Forward Guidance
Puma increased its financial guidance for full year 2022 to reflect improvements in U.S. demand for NERLYNX and changes to the timing of shipments to Puma’s international partners.
Positive Outlook
- Product sales, net (in millions): $194 - $196
- Royalties (in millions): $25 - $27
- Net income (in millions): $7 - $9
- Gross to net adjustment: 18% - 19%
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...